ACCEL RESEARCH SITES
LIVE

Serial Number

86955371

Owner

Clinical Research Holdings, LLC

Attorney

Mark A. Wright

Filing Date

Mar 28, 2016

Add to watchlist:

No watchlists yet
View on USPTO

ACCEL RESEARCH SITES Trademark

Serial Number: 86955371 • Registration: 5435841

ACCEL RESEARCH SITES is a trademark filed by Clinical Research Holdings, LLC on March 28, 2016. The trademark is classified under Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Clinical Research Holdings, LLC (5 trademarks)

615 Crescent Executive Court
Lake Mary, FL 32746

Entity Type: 16

Trademark Details

Filing Date

March 28, 2016

Registration Date

April 3, 2018

Published for Opposition

January 16, 2018

Goods & Services

Business consulting and management in the field of clinical trials in all phases as it relates to pre-study document collection and review, site selection, visits and audits, site compliance, project tracking and monitoring reports, negotiation and administration of investigator grants and clinical trial budgets and contracts, financial and management accounting, distribution, coordination and tracking of clinical trial products and materials, regulatory document processing, laboratory selection and coordination; Business consulting and management in the field of clinical trials in all phases as it relates to managing site and study-specific subject recruitment strategies and programs in the nature of contingency strategies and solutions to address specific project challenges; Business consulting and management in the field of clinical trials in all phases as it relates to managing the development of all study related documents and materials in the nature of study protocols, contracts, budgets, amendments, paper and electronic case report forms, informed consent forms, safety narratives, presentation posters, and training manuals; Business consulting and management in the field of clinical trials in all phases as it relates to managing all aspects of study, drug reconciliation, and inventory and distribution reports; Business management for all aspects of clinical trials in all phases as it relates to managing investigators, coordinators, monitors, technicians, and participants for compliance with clinical protocols and regulations; Business consulting and management in the field of clinical trials in all phases as it relates to management and compilation of computerized databases in the field of clinical trials for business purposes; Business consulting and management in the field of clinical trials in all phases as it relates to ethical reviews, namely, submitting clinical trial protocols to institutional review boards and independent ethics committees on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical trials; Statistical analysis and reporting services for business purposes in the field of clinical trials; Business project management in the field of clinical trials in all phases as it relates to organizing and conducting business meetings of clinical trial investigators; Business management, namely, managing randomization logistics, in the pharmaceutical and biotechnological field for business purposes; Development and implementation of personnel recruitment and retention programs for investigators, coordinators, monitors, technicians and participants for use in clinical trials; Business consulting and management in the field of clinical trials in all phases as it relates to the administration of protocols involving volunteer research patients and the recruiting of such volunteer research patients; Providing data management services in the medical, pharmaceutical and biotechnological field for business purposes

Regulatory affairs, namely, reviewing standards and practices to assure compliance with clinical trial laws and regulations; Providing independent review of clinical trials involving human subjects, namely, reviewing research protocols and related information to ensure protection of the rights and welfare of human subjects of research

Medical and scientific research consulting services for others in the field of design, planning, and implementation of clinical trials in all phases; providing quality assurance services in the pharmaceutical and biotechnological industries

Filing History

SEC. 15 ACKNOWLEDGEMENT - E-MAILED
Sep 14, 2025 NA15
REGISTERED - SEC. 15 ACKNOWLEDGED
Sep 14, 2025 15AK
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Sep 8, 2025 APRE
TEAS SECTION 15 RECEIVED
Aug 18, 2025 E15R
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Dec 19, 2024 NAS8
REGISTERED - SEC. 8 (6-YR) ACCEPTED
Dec 19, 2024 8.OK
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Dec 19, 2024 APRE
TEAS SECTION 8 RECEIVED
Apr 3, 2024 ES8R
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 29, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 29, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 29, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 29, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 29, 2024 COAR
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Apr 3, 2023 REM1
REGISTERED-PRINCIPAL REGISTER
Apr 3, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 16, 2018 NPUB
PUBLISHED FOR OPPOSITION
Jan 16, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 27, 2017 NONP
ASSIGNED TO LIE
Dec 6, 2017 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 28, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 9, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 9, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 9, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 9, 2017 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 23, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 23, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 23, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 19, 2017 GNRN
NON-FINAL ACTION E-MAILED
Oct 19, 2017 GNRT
NON-FINAL ACTION WRITTEN
Oct 19, 2017 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 28, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 27, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 27, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 24, 2017 GNRN
NON-FINAL ACTION E-MAILED
Aug 24, 2017 GNRT
NON-FINAL ACTION WRITTEN
Aug 24, 2017 CNRT
EXAMINER'S AMENDMENT ENTERED
Aug 2, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 2, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 2, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 2, 2017 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 6, 2017 GNRN
NON-FINAL ACTION E-MAILED
Feb 6, 2017 GNRT
NON-FINAL ACTION WRITTEN
Feb 6, 2017 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 11, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 11, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 11, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 15, 2016 GNRN
NON-FINAL ACTION E-MAILED
Jul 15, 2016 GNRT
NON-FINAL ACTION WRITTEN
Jul 15, 2016 CNRT
ASSIGNED TO EXAMINER
Jul 11, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 31, 2016 NWOS
NEW APPLICATION ENTERED
Mar 31, 2016 NWAP